<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of immune-mediated necrotizing myopathy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of immune-mediated necrotizing myopathy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of immune-mediated necrotizing myopathy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lisa Christopher-Stine, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ira N Targoff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeremy M Shefner, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H300503274"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Immune-mediated necrotizing myopathy (IMNM), also referred to as necrotizing autoimmune myopathy (NAM), is a distinct subgroup of the idiopathic inflammatory myopathies (IIMs). Randomized trials assessing the efficacy and safety of various immunosuppressive regimens for treating IMNM are absent owing to the rarity of the disease. Management is largely based on expert opinion and information from case series that describe symptom improvement and declining creatine kinase (CK) levels with the use of immunosuppressive medications.</p><p>The management and prognosis of IMNM will be discussed in this topic. The clinical manifestations and diagnosis of IMNM, as well as other topics related to the idiopathic inflammatory myopathies, are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/131941.html" rel="external">"Clinical manifestations and diagnosis of immune-mediated necrotizing myopathy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/127066.html" rel="external">"Overview of and approach to the idiopathic inflammatory myopathies"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14918.html" rel="external">"Pathogenesis of inflammatory myopathies"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5159.html" rel="external">"Clinical manifestations of dermatomyositis and polymyositis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15653.html" rel="external">"Diagnosis and differential diagnosis of dermatomyositis and polymyositis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5160.html" rel="external">"Initial treatment of dermatomyositis and polymyositis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/13774.html" rel="external">"Management of refractory cutaneous dermatomyositis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5163.html" rel="external">"Clinical manifestations and diagnosis of inclusion body myositis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5164.html" rel="external">"Management of inclusion body myositis"</a>.)</p><p></p><p class="headingAnchor" id="H3098048152"><span class="h1">GENERAL PRINCIPLES</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of therapy</strong> – The goal of therapy in patients with immune-mediated necrotizing myopathy (IMNM) is to achieve longstanding remission; however, given disease variability, this is often not possible and additional goals include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decreasing muscle weakness</p><p class="bulletIndent2"><span class="glyph">•</span>Increasing endurance</p><p class="bulletIndent2"><span class="glyph">•</span>Minimizing atrophy and functional disability that is irreversible</p><p class="bulletIndent2"><span class="glyph">•</span>Addressing quality-of-life measures most meaningful to patient</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Principles of management</strong> – The following general principles are important to help guide therapy and achieve treatment goals:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Initiate prompt, early therapy, which may improve clinical outcomes [<a href="#rid1">1</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Use an aggressive treatment strategy that often requires combination therapy</p><p class="bulletIndent2"><span class="glyph">•</span>Minimize long-term steroid use</p><p class="bulletIndent2"><span class="glyph">•</span>Titrate therapeutic immunosuppressive/immunomodulatory agents to the lowest possible doses once the disease is stabilized (preferably with full-strength and creatine kinase [CK] normalization)</p><p class="bulletIndent2"><span class="glyph">•</span>Encourage resistance exercises as tolerated as an adjunct to pharmacotherapy</p><p class="bulletIndent2"><span class="glyph">•</span>Evaluate for dysphagia and treat if necessary to avoid aspiration and maximize nutrition</p><p></p><p class="headingAnchor" id="H906651690"><span class="h1">INITIAL MANAGEMENT</span><span class="headingEndMark"> — </span>There are no widely accepted standard practices, treat-to-target goals, or validated disease-specific patient-reported outcomes for immune-mediated necrotizing myopathy (IMNM). Treatment is largely based on expert opinion, limited observational data from cases of IMNM, and indirect evidence from the treatment of dermatomyositis and other inflammatory myopathies. Our approach is generally consistent with expert consensus-driven treatment guidelines for anti-signal-recognition particle (SRP) IMNM and anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) IMNM that have been proposed [<a href="#rid2">2</a>]. No specific treatment guidelines for seronegative IMNM have been proposed.</p><p class="headingAnchor" id="H4109290102"><span class="h2">Assessment of disease severity</span><span class="headingEndMark"> — </span>Our approach to initial therapy depends in part upon the disease severity. Specific medication choices are also guided by antibody positivity (ie, anti-HMGCR or anti-SRP antibodies) when known. We define disease severity as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe disease</strong> – Patients with severe IMNM include those with severe or rapidly progressive weakness resulting in difficulty walking, dysphagia, respiratory failure, and/or other severe organ damage including rapid progression to muscle atrophy and fatty replacement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Non-severe disease</strong> – Patients with nonsevere IMNM include those who do not have difficulty walking, dysphagia, or other end-organ damage.</p><p></p><p class="headingAnchor" id="H3923038072"><span class="h2">Severe disease</span><span class="headingEndMark"> — </span>Most patients with severe IMNM will require prompt treatment with immunosuppressive therapy with a combination of glucocorticoids and either intravenous immunoglobulin (<a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>) or <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>. The approach to immunosuppressive therapy is generally based on whether the patient is anti-SRP-positive or anti-HMGCR-positive. (See <a class="local">'Anti-SRP-positive'</a> below and <a class="local">'Anti-HMGCR-positive'</a> below and <a class="local">'Seronegative or unknown antibody status'</a> below.)</p><p class="headingAnchor" id="H1439944496"><span class="h3">Anti-SRP-positive</span><span class="headingEndMark"> — </span>For most patients with anti-SRP-positive IMNM, we suggest initial treatment with intravenous glucocorticoids combined with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>.</p><p>For patients with very severe disease, we suggest adding <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> to this regimen. <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a> or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> may be substituted for methotrexate when it is contraindicated or not tolerated. If there is an adequate clinical response within three to six months, then the glucocorticoids are tapered to the lowest possible dose as tolerated.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong> – We administer IV pulse <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> 500 to 1000 mg daily for three days prior to the initiation of oral glucocorticoids. Oral glucocorticoid therapy is then started at 0.5 to 1 mg/kg daily of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (or its equivalent) and tapered gradually according to patient response to additional therapy with a glucocorticoid-sparing agent. Similar to other idiopathic inflammatory myopathies, prednisone is typically decreased by 20 to 25 percent of the existing dose monthly, with the goal of achieving a low daily dose (eg, prednisone 5 mg daily) or discontinuation by four to six months [<a href="#rid3">3</a>]. There are no standard glucocorticoid tapering regimens, but a reasonable approach is one that we use for dermatomyositis, which is described separately. (See  <a class="medical medical_review" href="/d/html/5160.html" rel="external">"Initial treatment of dermatomyositis and polymyositis in adults", section on 'Glucocorticoid tapering'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">Rituximab</a> is typically administered as a dose of 1000 mg, given twice, two weeks apart, by IV infusion. However, some studies have suggested that a lower dose, either 500 mg given twice two weeks apart or 1000 mg given once, may be adequate. This approach is generally consistent with the dosing used for rheumatoid arthritis, which is discussed separately (see  <a class="medical medical_review" href="/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis", section on 'Initial dose'</a>). Additional information regarding pretreatment testing, immunizations and response to vaccines, and adverse effects is presented separately. (See  <a class="medical medical_review" href="/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis", section on 'Immunizations and baseline studies'</a> and  <a class="medical medical_review" href="/d/html/7501.html" rel="external">"Rituximab: Principles of use and adverse effects in rheumatoid arthritis", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> is typically initiated at a dose of 10 to 15 mg/week, with increases in dose every two to eight weeks of 5 mg/week up to 25 mg/week. We use the same regimen and approach to titration as that used in rheumatoid arthritis. Additional information regarding dosing, pretreatment precautions, and adverse effects is presented separately. (See  <a class="medical medical_review" href="/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Dosing and administration'</a> and  <a class="medical medical_review" href="/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The use of <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> for patients with anti-SRP-positive disease is supported by observational data from case series, along with expert experience [<a href="#rid4">4,5</a>]. In a case series including eight patients with refractory anti-SRP-positive IMNM, six patients demonstrated a decrease in creatine kinase (CK) levels and improved strength with rituximab [<a href="#rid5">5</a>]. The patients included in the study had an inadequate response to various other therapies that included <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>. In another larger case series in which treatments were individualized, 13 of 17 patients with anti-SRP-positive IMNM responded well to rituximab [<a href="#rid4">4</a>]. Some patients required retreatment after one year, and others recovered strength more than two years after the first dose.</p><p></p><p class="bulletIndent1">The efficacy of <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> for IMNM is based on expert opinion, our clinical experience, case series, and its use in treating other inflammatory myopathies [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/5160.html" rel="external">"Initial treatment of dermatomyositis and polymyositis in adults", section on 'Methotrexate'</a>.)</p><p></p><p class="headingAnchor" id="H3785442054"><span class="h3">Anti-HMGCR-positive</span><span class="headingEndMark"> — </span>For most patients with anti-HMGCR-positive IMNM, we suggest treatment with intravenous glucocorticoids combined with <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>. However, monotherapy with IVIG is a reasonable alternative and may be preferred in patients who are at increased risk of developing glucocorticoid-related side effects (eg, patients with diabetes). <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> may also be added to this regimen.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong> – The dosing of glucocorticoids and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> is described above. (See <a class="local">'Anti-SRP-positive'</a> above.)</p><p></p><p class="bulletIndent1">We typically give a total of 2 g/kg of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> per month, often administered as 1g/kg divided over two consecutive days or as 0.4 g/kg divided over five consecutive days. IVIG is usually administered for at least five months and often must be continued for years. Serious adverse effects associated with IVIG include anaphylaxis, thromboembolic events, transfusion-associated lung injury, and others and are discussed separately. (See  <a class="medical medical_review" href="/d/html/4431.html" rel="external">"Overview of intravenous immune globulin (IVIG) therapy", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – The use of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> has been associated with partial and complete remissions in cases of anti-HMGCR-positive patients [<a href="#rid1">1,6,7</a>]. Monotherapy with IVIG in the absence of glucocorticoids has also been shown to be effective in some patients, especially those with a contraindication to steroid use, and can reduce complications in patients with comorbidities such as diabetes mellitus DM [<a href="#rid8">8,9</a>]. In the author’s experience, IVIG monotherapy has been effective in many cases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of statins</strong> – Reintroduction or initiation of statins should be avoided in patients with anti-HMGCR-positive IMNM given the potential risk of disease flare [<a href="#rid10">10-12</a>].</p><p></p><p class="headingAnchor" id="H1460454138"><span class="h3">Seronegative or unknown antibody status</span><span class="headingEndMark"> — </span>Patients with severe disease who are seronegative or have an unknown antibody status may be treated just as those with either anti-SRP-positive or anti-HMGCR-positive myopathy. The decision to treat with specific therapies (ie, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>) depends on several factors including considerations regarding comorbidities, patient preferences, and availability of specific agents. As an example, IVIG should be avoided in patients with congestive heart failure or previous unprovoked deep venous thrombosis.</p><p class="headingAnchor" id="H2131202479"><span class="h2">Nonsevere disease</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial therapy</strong> – For most patients with nonsevere IMNM, we suggest initial treatment with oral glucocorticoids in combination with <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>. <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a> or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> may be substituted for methotrexate if it is contraindicated or not tolerated. (See  <a class="medical medical_review" href="/d/html/5160.html" rel="external">"Initial treatment of dermatomyositis and polymyositis in adults", section on 'Azathioprine'</a> and  <a class="medical medical_review" href="/d/html/5133.html" rel="external">"Treatment of recurrent and resistant dermatomyositis and polymyositis in adults", section on 'Mycophenolate mofetil'</a>.)</p><p></p><p class="bulletIndent1">Oral glucocorticoid therapy is typically started at 0.5 to 1 mg/kg/day of <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> (or equivalent). Glucocorticoids are then gradually tapered to the lowest dose as tolerated in the same manner as described above for severe disease. (See <a class="local">'Anti-SRP-positive'</a> above.)</p><p></p><p class="bulletIndent1">The dosing and rationale for using <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> is the same as that for severe disease. (See <a class="local">'Anti-SRP-positive'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent treatment</strong> – For patients who do not adequately respond to initial therapy with glucocorticoids and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> after three to six months, the subsequent choice of glucocorticoid-sparing agent depends upon whether the patient is anti-SRP-positive or anti-HMGCR-positive and generally follows the same approach as severe disease:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with IMNM who are anti-SRP-positive, we add <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> to the initial treatment regimen and reassess the response after another three to six months. Rituximab is typically continued every six months for at least two years of well-controlled disease. (See <a class="local">'Anti-SRP-positive'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with IMNM who are anti-HMGCR-positive, we add <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> to the initial treatment regimen. IVIG is typically dosed at 2 g/kg/month for at least five months and often must be continued for years. IVIG monotherapy in the absence of glucocorticoids may be effective in some patients. (See <a class="local">'Anti-HMGCR-positive'</a> above.)</p><p></p><p class="headingAnchor" id="H1795328055"><span class="h2">Monitoring treatment response</span><span class="headingEndMark"> — </span>The majority of patients with IMNM require long-term immunosuppressive therapy. When therapy is tapered off, the disease often flares. Most therapies are continued for at least one to two years. The goal is to use the lowest number of therapeutic agents needed to maintain remission.</p><p>All patients receiving immunosuppressive therapy for IMNM should be closely monitored. Monitoring response to therapy is mostly clinical and includes serial assessments of muscle strength and endurance. Clinicians should be aware that fatigability, decreased endurance, and sometimes pain can linger despite normal strength [<a href="#rid13">13</a>]. Many experts agree that improvement to a stable muscle strength that may not approximate baseline strength is still an indication of clinical response to therapy.</p><p>Patients should also be assessed for toxicity to the medication regimen (eg, adverse effects, infections due to immunosuppression).</p><p>We generally include the following labs during follow-up visits:</p><p class="bulletIndent1"><span class="glyph">●</span>CK</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count</p><p class="bulletIndent1"><span class="glyph">●</span>Complete metabolic panel</p><p></p><p>CK levels often do not normalize, but we try to achieve a level below 1000 international units/L. While we aim for full remission of symptoms, it is possible that atrophy and fatty replacement of the muscles will persist from disease damage. Thus, there may be residual muscle weakness that is not amenable to further immunosuppressive therapy. Magnetic resonance imaging (MRI) can be instructive in such a situation as it can help distinguish fatty replacement within the muscles from persistent muscular edema. The presence of fatty replacement in the absence of edema would generally not mandate further aggressive treatment; however, because whole-body MRI is not routinely performed, it is conceivable that there could be residual inflammation elsewhere such as the upper extremities, Thus, if upper-extremity weakness and elevated CK persist, there may indeed be residual disease activity.</p><p class="headingAnchor" id="H926551024"><span class="h2">Rehabilitation</span><span class="headingEndMark"> — </span>For all patients with IMNM, we suggest physical therapy. Exercise appears to be beneficial across all idiopathic inflammatory myopathy (IIM) subclasses [<a href="#rid14">14,15</a>]. Resistance exercises with light weights and increased repetitions are associated with a decreased immune response, increased aerobic metabolism, and decreased muscular atrophy [<a href="#rid16">16</a>]. Exercise induces microRNAs that target transcripts and proteins important for muscle and immune response.</p><p>In addition, referral to a speech therapist for diagnosis and management of dysphagia when present is imperative to maximize nutritional intake and to help prevent aspiration pneumonia.</p><p class="headingAnchor" id="H555740373"><span class="h1">RELAPSING OR REFRACTORY DISEASE</span><span class="headingEndMark"> — </span>A clinical relapse is defined by a recurrence of signs or symptoms of active disease including weakness and elevated creatine kinases (CKs). In most cases of relapse, we typically restart an induction therapy that includes either <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or intravenous immunoglobulin (<a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>).</p><p>Patients with refractory disease are those who continue to have persistent weakness and/or elevated CKs despite optimal immunosuppressive therapy for an adequate period (usually up to six months). In such patients, it may be necessary to try alternative medications. Other medications that have been used include <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a>, and <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a>, although the evidence to guide choosing any specific agent is limited [<a href="#rid2">2</a>]. Plasmapheresis has been used in patients with refractory disease, but there are few published reports [<a href="#rid17">17-19</a>].</p><p class="headingAnchor" id="H50653556"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The prognosis is variable among immune-mediated necrotizing myopathy (IMNM) patients; however, younger seropositive patients appear to fare worse clinically than older patients [<a href="#rid4">4</a>]. This is particularly notable in anti-signal-recognition particle (SRP) patients; younger patients are weaker at the first clinic visit and they remain weaker than older patients subsequently, even after accounting for confounders [<a href="#rid4">4,20</a>]. Disease severity appears to be increased in anti-SRP-positive myopathy and statin-naïve, younger, anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR)-positive myopathy, and it is more destructive in females and African American patients [<a href="#rid4">4,21</a>].</p><p>However, with regard to anti-HMGCR-positive myopathy, younger patients are more often statin naïve; thus, it is unclear if the statin-naïve state or the younger age is the risk factor for worse prognosis. For example, one study noted that compared with statin-associated anti-HMGCR-positive IMNM, statin-naïve anti-HMGCR-positive IMNM patients more frequently required third-line therapy (50 versus 9 percent) and had a poor to fatal outcome (50 versus 0 percent) [<a href="#rid22">22</a>].</p><p>With regard to anti-SRP-positive myopathy, observational data have shown that the clinical risk factors for refractory patients include male sex (odds ratio [OR] 19.57), severe muscle weakness (OR 7.51), and concurrent interstitial lung disease (OR 39.7) [<a href="#rid23">23</a>]. On imaging, the rate of fatty infiltration of thigh muscles over three months was also predictive of refractory disease.</p><p class="headingAnchor" id="H3559255813"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/114586.html" rel="external">"Society guideline links: Dermatomyositis and polymyositis"</a>.)</p><p class="headingAnchor" id="H4009147547"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of therapy</strong> – The goal of therapy is to achieve longstanding remission. However, this is not always achieved. Other treatment goals include (see <a class="local">'General principles'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Decreasing muscle weakness</p><p class="bulletIndent2"><span class="glyph">•</span>Increasing endurance</p><p class="bulletIndent2"><span class="glyph">•</span>Minimizing functional disability</p><p class="bulletIndent2"><span class="glyph">•</span>Improving quality of life </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Most patients with immune-mediated necrotizing myopathy (IMNM) require long-term immunosuppressive therapy. When therapy is tapered off, the disease often flares. The goal is to use the lowest number of therapeutic agents needed to maintaining remission. Most therapies are continued for at least one to two years.</p><p></p><p class="bulletIndent1">Treatment recommendations are based on expert opinion, limited observational data, and indirect evidence from the treatment of dermatomyositis and other inflammatory myopathies. (See <a class="local">'Initial management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factors that guide initial therapy</strong> – Our approach to initial therapy depends upon the disease severity (see <a class="local">'Assessment of disease severity'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe disease</strong> – Patients with severe IMNM include those with severe or rapidly progressive weakness resulting in difficulty walking, dysphagia, respiratory failure, and/or other severe organ damage.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonsevere disease</strong> – Patients with nonsevere IMNM include those who do not have difficulty walking or dysphagia.</p><p></p><p class="bulletIndent1">Specific medication choices are also guided by antibody positivity (ie, anti-3-hydroxy-3-methylglutaryl coenzyme A reductase [HMGCR] or anti-signal-recognition particle [SRP] antibodies) when known.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of severe disease</strong> – The approach to immunosuppressive therapy for patients with severe disease is generally guided by the patient’s autoantibody status.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anti-SRP-positive</strong> – For most patients with anti-SRP-positive IMNM, we suggest treatment with intravenous (IV) glucocorticoids combined with <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> may be added to this regimen for patients with more severe disease.</p><p></p><p class="bulletIndent2">If there is an adequate clinical response within three to six months, then the glucocorticoids are tapered to the lowest possible dose as tolerated. (See <a class="local">'Anti-SRP-positive'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anti-HMGCR-positive</strong> – For most patients with anti-HMGCR-positive IMNM, we suggest treatment with IV glucocorticoids combined with <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> may be added to this regimen.</p><p></p><p class="bulletIndent2">Glucocorticoids are tapered according to clinical response. (See <a class="local">'Anti-HMGCR-positive'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Seronegative or unknown antibody status</strong> – Patients with severe disease who are seronegative or have an unknown antibody status are treated as those with either anti-SRP-positive or anti-HMGCR-positive myopathy. The decision to treat with specific therapies (ie, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or intravenous immunoglobulin [<a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>]) depends on several factors including considerations regarding comorbidities, patient preferences, and availability of specific agents. (See <a class="local">'Seronegative or unknown antibody status'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of nonsevere disease</strong> – For most patients with nonsevere IMNM, we suggest initial treatment with oral glucocorticoids in combination with <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a> or <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> may be substituted for methotrexate if it is contraindicated or not tolerated.</p><p></p><p class="bulletIndent1">For patients who do not adequately respond to initial therapy with glucocorticoids and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> after three to six months, the subsequent choice of glucocorticoid-agent depends upon whether the patient is anti-SRP-positive or anti-HMGCR-positive and generally follows the same approach as for severe disease. (See <a class="local">'Nonsevere disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other treatment considerations</strong> – Exercise appears to be beneficial; we refer all patients to physical therapy. In addition, referral to a speech therapist for diagnosis and management of dysphagia is imperative to maximize nutritional intake and to help prevent aspiration pneumonia. (See <a class="local">'Rehabilitation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring response to therapy</strong> – Monitoring response to therapy includes serial assessments of muscle strength and endurance. (See <a class="local">'Monitoring treatment response'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapsing or refractory disease</strong> – In most cases of relapse, we typically restart an induction therapy that includes either <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">IVIG</a>. (See <a class="local">'Relapsing or refractory disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The prognosis is variable. Younger seropositive patients appear to fare worse clinically than older patients. (See <a class="local">'Prognosis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kassardjian CD, Lennon VA, Alfugham NB, et al. Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy. JAMA Neurol 2015; 72:996.</a></li><li><a class="nounderline abstract_t">Allenbach Y, Mammen AL, Benveniste O, et al. 224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016. Neuromuscul Disord 2018; 28:87.</a></li><li><a class="nounderline abstract_t">Oddis CV, Aggarwal R. Treatment in myositis. Nat Rev Rheumatol 2018; 14:279.</a></li><li><a class="nounderline abstract_t">Pinal-Fernandez I, Parks C, Werner JL, et al. Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle. Arthritis Care Res (Hoboken) 2017; 69:263.</a></li><li><a class="nounderline abstract_t">Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 2010; 62:1328.</a></li><li><a class="nounderline abstract_t">Allenbach Y, Drouot L, Rigolet A, et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) 2014; 93:150.</a></li><li><a class="nounderline abstract_t">Pitlick M, Ernste F. Anti-HMGCR myopathy presenting with acute systolic heart failure. BMJ Case Rep 2019; 12.</a></li><li><a class="nounderline abstract_t">Mammen AL, Tiniakou E. Intravenous Immune Globulin for Statin-Triggered Autoimmune Myopathy. N Engl J Med 2015; 373:1680.</a></li><li><a class="nounderline abstract_t">Lim J, Eftimov F, Verhamme C, et al. Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study. Rheumatology (Oxford) 2021; 60:1784.</a></li><li><a class="nounderline abstract_t">Grable-Esposito P, Katzberg HD, Greenberg SA, et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010; 41:185.</a></li><li><a class="nounderline abstract_t">Mammen AL. Statin-Associated Autoimmune Myopathy. N Engl J Med 2016; 374:664.</a></li><li><a class="nounderline abstract_t">Tiniakou E, Christopher-Stine L. Immune-mediated necrotizing myopathy associated with statins: history and recent developments. Curr Opin Rheumatol 2017; 29:604.</a></li><li><a class="nounderline abstract_t">Amici DR, Pinal-Fernandez I, Pagkatipunan R, et al. Muscle endurance deficits in myositis patients despite normal manual muscle testing scores. Muscle Nerve 2019; 59:70.</a></li><li><a class="nounderline abstract_t">Habers GE, Takken T. Safety and efficacy of exercise training in patients with an idiopathic inflammatory myopathy--a systematic review. Rheumatology (Oxford) 2011; 50:2113.</a></li><li><a class="nounderline abstract_t">Alemo Munters L, Dastmalchi M, Andgren V, et al. Improvement in health and possible reduction in disease activity using endurance exercise in patients with established polymyositis and dermatomyositis: a multicenter randomized controlled trial with a 1-year open extension followup. Arthritis Care Res (Hoboken) 2013; 65:1959.</a></li><li><a class="nounderline abstract_t">Boehler JF, Hogarth MW, Barberio MD, et al. Effect of endurance exercise on microRNAs in myositis skeletal muscle-A randomized controlled study. PLoS One 2017; 12:e0183292.</a></li><li><a class="nounderline abstract_t">Ramanathan S, Langguth D, Hardy TA, et al. Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy. Neurol Neuroimmunol Neuroinflamm 2015; 2:e96.</a></li><li><a class="nounderline abstract_t">Arlet JB, Dimitri D, Pagnoux C, et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord 2006; 16:334.</a></li><li><a class="nounderline abstract_t">Kruse RL, Albayda J, Vozniak SO, et al. Therapeutic plasma exchange for the treatment of refractory necrotizing autoimmune myopathy. J Clin Apher 2022; 37:253.</a></li><li><a class="nounderline abstract_t">Tiniakou E, Pinal-Fernandez I, Lloyd TE, et al. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology (Oxford) 2017; 56:787.</a></li><li><a class="nounderline abstract_t">Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis 2017; 76:681.</a></li><li><a class="nounderline abstract_t">Lim J, Rietveld A, De Bleecker JL, et al. Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy. Neurol Neuroimmunol Neuroinflamm 2019; 6:e513.</a></li><li><a class="nounderline abstract_t">Zhao Y, Zhang W, Liu Y, et al. Factors associated with refractory autoimmune necrotizing myopathy with anti-signal recognition particle antibodies. Orphanet J Rare Dis 2020; 15:181.</a></li></ol></div><div id="topicVersionRevision">Topic 135000 Version 1.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26192196" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29221629" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29593343" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Treatment in myositis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27111848" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20506493" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24797170" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31068355" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Anti-HMGCR myopathy presenting with acute systolic heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26488714" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Intravenous Immune Globulin for Statin-Triggered Autoimmune Myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33099648" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Intravenous immunoglobulins as first-line treatment in idiopathic inflammatory myopathies: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19813188" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Immune-mediated necrotizing myopathy associated with statins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26886523" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Statin-Associated Autoimmune Myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28857949" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Immune-mediated necrotizing myopathy associated with statins: history and recent developments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30028529" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Muscle endurance deficits in myositis patients despite normal manual muscle testing scores.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21890619" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Safety and efficacy of exercise training in patients with an idiopathic inflammatory myopathy--a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23861241" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Improvement in health and possible reduction in disease activity using endurance exercise in patients with established polymyositis and dermatomyositis: a multicenter randomized controlled trial with a 1-year open extension followup.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28829792" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effect of endurance exercise on microRNAs in myositis skeletal muscle-A randomized controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25866831" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16616848" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35119135" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Therapeutic plasma exchange for the treatment of refractory necrotizing autoimmune myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28096458" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27651398" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30345336" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32641139" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Factors associated with refractory autoimmune necrotizing myopathy with anti-signal recognition particle antibodies.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
